KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Short-term Investments: 2013-2024

Historic Short-term Investments for Halozyme Therapeutics (HALO) over the last 12 years, with Dec 2024 value amounting to $480.2 million.

  • Halozyme Therapeutics' Short-term Investments fell 44.86% to $282.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $282.3 million, marking a year-over-year decrease of 44.86%. This contributed to the annual value of $480.2 million for FY2024, which is 120.66% up from last year.
  • Halozyme Therapeutics' Short-term Investments amounted to $480.2 million in FY2024, which was up 120.66% from $217.6 million recorded in FY2023.
  • Over the past 5 years, Halozyme Therapeutics' Short-term Investments peaked at $622.2 million during FY2021, and registered a low of $128.6 million during FY2022.
  • In the last 3 years, Halozyme Therapeutics' Short-term Investments had a median value of $217.6 million in 2023 and averaged $275.5 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Short-term Investments soared by 182.42% in 2021, and later tumbled by 79.33% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Short-term Investments (Yearly) stood at $220.3 million in 2020, then skyrocketed by 182.42% to $622.2 million in 2021, then slumped by 79.33% to $128.6 million in 2022, then spiked by 69.23% to $217.6 million in 2023, then soared by 120.66% to $480.2 million in 2024.